Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Upgraded by JP Morgan

NEW YORK (GenomeWeb News) – Investment bank JP Morgan has upgraded Beckman Coulter's stock to "overweight" from "neutral," due to the firm's long-range earnings forecast.

In mid-December, Beckman Coulter set a preliminary 2010 guidance for adjusted earnings per share of between $4.40 and $4.55, which was just below analysts' consensus estimate of $4.56.

JP Morgan also set a 12-month price target on the stock of $75.

In early Monday trade on the New York Stock Exchange, shares of Beckman Coulter were up around 2 percent at $67.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.